Research programme: eye surgery therapeutics - Schering-Plough
Alternative Names: rAd-p21Latest Information Update: 24 Aug 2009
At a glance
- Originator Schering-Plough; University of Wisconsin-Madison
- Class Gene therapies
- Mechanism of Action Angiogenesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Wounds
Most Recent Events
- 24 Aug 2009 Discontinued - Preclinical for Wounds in USA (unspecified route)